Abstract：
BACKGROUND: Okra (Abelmoschus esculentus (L.) Moench) is traditionally used by different populations of Africa, América, Asia, and Europa to control diabetes. Although its action has been evaluated in several preclinical rodent trials, they have not been systematically analyzed.
OBJECTIVE: To evaluate the effectiveness of using okra in the treatment of diabetes in experimental rodent models.
METHODS: Controlled and randomized rodent animal trials with induced diabetes published between January 2000 and January 2021 were searched in the PubMed, Scopus, Scielo, and Web of Science databases. The search strategy included studies comprising the descriptors: animal species, diabetes induction method, intervention time, part of okra fruit used (whole, seeds, or peels), and dose as well as observed effects on biochemical and metabolic parameters. The systematic review was carried out according to the PRISMA statement, Cochrane bias risk tool (SYRCLE\'s RoB tool), and registered for systematic review protocols (PROSPERO).
RESULTS: A total of 326 articles were identified and after the exclusion of studies with gestational animal models, non-rodent animals, and non-diabetic animals, 11 studies involving 388 rodents were selected for the synthesis of results. The diabetes induction methods included streptozotocin, streptozotocin-nicotinamide, alloxan monohydrate, insulin resistance by high-fat diets or formulation described in AIN - 76, and feeding with high-fat food. Both Wistar albino rats, Sprague-Dawley males, and rats of both sexes of the Long-Evans lineage as well as male albino mice and C57BL females were included in the experiments. Studies showed that extracts of the fruit, the fresh fruit, or its various fractions had positive effects on the following markers: glycated hemoglobin, cholesterol, HOMA-IR, oral glucose tolerance test, and blood glucose, in acute (2 and 24 h), and chronic (up to 4 months) treatment.
CONCLUSIONS: An important hypoglycemic effect of okra in its various fractions on induced diabetes was observed by different authors. Moreover, okra promoted improvement in metabolic markers such as insulin sensitivity, lipid profile, and bodyweight loss.
OBJECTIVE: To evaluate the effectiveness of using okra in the treatment of diabetes in experimental rodent models.
METHODS: Controlled and randomized rodent animal trials with induced diabetes published between January 2000 and January 2021 were searched in the PubMed, Scopus, Scielo, and Web of Science databases. The search strategy included studies comprising the descriptors: animal species, diabetes induction method, intervention time, part of okra fruit used (whole, seeds, or peels), and dose as well as observed effects on biochemical and metabolic parameters. The systematic review was carried out according to the PRISMA statement, Cochrane bias risk tool (SYRCLE\'s RoB tool), and registered for systematic review protocols (PROSPERO).
RESULTS: A total of 326 articles were identified and after the exclusion of studies with gestational animal models, non-rodent animals, and non-diabetic animals, 11 studies involving 388 rodents were selected for the synthesis of results. The diabetes induction methods included streptozotocin, streptozotocin-nicotinamide, alloxan monohydrate, insulin resistance by high-fat diets or formulation described in AIN - 76, and feeding with high-fat food. Both Wistar albino rats, Sprague-Dawley males, and rats of both sexes of the Long-Evans lineage as well as male albino mice and C57BL females were included in the experiments. Studies showed that extracts of the fruit, the fresh fruit, or its various fractions had positive effects on the following markers: glycated hemoglobin, cholesterol, HOMA-IR, oral glucose tolerance test, and blood glucose, in acute (2 and 24 h), and chronic (up to 4 months) treatment.
CONCLUSIONS: An important hypoglycemic effect of okra in its various fractions on induced diabetes was observed by different authors. Moreover, okra promoted improvement in metabolic markers such as insulin sensitivity, lipid profile, and bodyweight loss.
摘要：
背景：秋葵（Abelmoschusesculentus（L.)Moench)传统上被非洲的不同人口使用，美国,亚洲,和欧罗巴来控制糖尿病。尽管它的作用已经在一些临床前啮齿动物试验中得到了评估，他们没有被系统地分析。
目的：在实验性啮齿动物模型中评估使用秋葵治疗糖尿病的有效性。
方法：在PubMed中检索了2000年1月至2021年1月之间发表的诱发糖尿病的对照和随机啮齿动物试验，Scopus,Scielo,和WebofScience数据库。搜索策略包括包含描述符的研究：动物物种，糖尿病诱导方法,干预时间,部分使用的秋葵果实(整个，种子,或果皮)，和剂量以及观察到的对生化和代谢参数的影响。系统审查是根据PRISMA声明进行的，Cochrane偏差风险工具(SYRCLE的RoB工具)，并注册了系统审查协议(PROSPERO)。
结果：共确定了326篇文章，在排除妊娠动物模型研究后，非啮齿动物,和非糖尿病动物，选择了11项涉及388只啮齿动物的研究来合成结果。糖尿病诱导方法包括链脲佐菌素，链脲佐菌素-烟酰胺，四氧嘧啶一水合物,通过AIN-76中描述的高脂肪饮食或配方以及用高脂肪食物喂养的胰岛素抵抗。两只Wistar白化病老鼠，Sprague-Dawley雄性,实验包括Long-Evans谱系的两种性别的大鼠以及雄性白化病小鼠和C57BL雌性。研究表明，水果的提取物，新鲜水果,或其各种组分对以下标志物有积极影响：糖化血红蛋白，胆固醇,HOMA-IR,口服葡萄糖耐量试验,和血糖，在急性（2和24小时），和慢性（长达4个月）治疗。
结论：不同作者观察到秋葵各部分对诱导糖尿病的重要降血糖作用。此外，秋葵促进代谢标志物如胰岛素敏感性的改善，血脂谱,和减肥。
目的：在实验性啮齿动物模型中评估使用秋葵治疗糖尿病的有效性。
方法：在PubMed中检索了2000年1月至2021年1月之间发表的诱发糖尿病的对照和随机啮齿动物试验，Scopus,Scielo,和WebofScience数据库。搜索策略包括包含描述符的研究：动物物种，糖尿病诱导方法,干预时间,部分使用的秋葵果实(整个，种子,或果皮)，和剂量以及观察到的对生化和代谢参数的影响。系统审查是根据PRISMA声明进行的，Cochrane偏差风险工具(SYRCLE的RoB工具)，并注册了系统审查协议(PROSPERO)。
结果：共确定了326篇文章，在排除妊娠动物模型研究后，非啮齿动物,和非糖尿病动物，选择了11项涉及388只啮齿动物的研究来合成结果。糖尿病诱导方法包括链脲佐菌素，链脲佐菌素-烟酰胺，四氧嘧啶一水合物,通过AIN-76中描述的高脂肪饮食或配方以及用高脂肪食物喂养的胰岛素抵抗。两只Wistar白化病老鼠，Sprague-Dawley雄性,实验包括Long-Evans谱系的两种性别的大鼠以及雄性白化病小鼠和C57BL雌性。研究表明，水果的提取物，新鲜水果,或其各种组分对以下标志物有积极影响：糖化血红蛋白，胆固醇,HOMA-IR,口服葡萄糖耐量试验,和血糖，在急性（2和24小时），和慢性（长达4个月）治疗。
结论：不同作者观察到秋葵各部分对诱导糖尿病的重要降血糖作用。此外，秋葵促进代谢标志物如胰岛素敏感性的改善，血脂谱,和减肥。
